Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders

被引:6
作者
Arakawa, Naoya [1 ]
Yagi, Hisako [1 ]
Shimizu, Mariko [2 ]
Shigeta, Daisuke [3 ]
Shimizu, Akihiko [2 ]
Nomura, Shigeru [2 ]
Takizawa, Takumi [1 ]
Yamada, Yoshiyuki [2 ,4 ]
机构
[1] Gunma Univ, Dept Pediat, Grad Sch Med, 3-39-22 Showa Machi, Gunma 3718511, Japan
[2] Gunma Childrens Med Ctr, Div Allergy & Immunol, 779 Shimohakoda, Shibukawa, Gunma 3778577, Japan
[3] Saku Cent Hosp Adv Care Ctr, Dept Pediat, 3400-28 Nakagomi, Saku, Nagano 3850051, Japan
[4] Tokai Univ, Dept Pediat, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan
关键词
dupilumab; biologic; eosinophil; eosinophilic gastrointestinal disorder (EGID); non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorder (EGID) (non-EoE EGID); elimination diet; GASTROENTERITIS; EFFICACY; GASTRITIS; ANTIBODY; CHILDREN;
D O I
10.3390/biom13010112
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first case based on a systematic search of non-EoE EGID for which tolerance to causative foods and histological and symptomatic improvements were achieved following dupilumab administration, after elimination diets and omalizumab and mepolizumab treatments. Driven by this case, we investigated the efficacies of biological treatments in non-EoE EGID cases based on the patient studied herein, and other patients identified in the conducted systematic review. Seven articles, including five different biologics, were reviewed. Both clinical efficacies and impact differences among the targeted molecules are demonstrated in this study. Our findings show that dupilumab may affect mechanisms that can suppress symptoms induced by offending foods that are different from those induced by other biologics as identified in the conducted systematic review. Additional studies are required to address the unmet needs of non-EoE EGID treatments.
引用
收藏
页数:10
相关论文
共 34 条
[11]   Anti-IgE treatment of eosinophil-associated gastrointestinal disorders [J].
Foroughi, Shabnam ;
Foster, Barbara ;
Kim, NaYoung ;
Bernardino, Leigh B. ;
Scott, Linda M. ;
Hamilton, Robert G. ;
Metcalfe, Dean D. ;
Mannon, Peter J. ;
Prussin, Calman .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (03) :594-601
[12]   Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia [J].
Friesen, CA ;
Kearns, GL ;
Andre, L ;
Neustrom, M ;
Roberts, CC ;
Abdel-Rahman, SM .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2004, 38 (03) :343-351
[13]   Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab [J].
Grandinetti, Tanja ;
Biedermann, Luc ;
Bussmann, Christian ;
Straumann, Alex ;
Hruz, Petr .
DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (08) :2231-2241
[14]   Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab [J].
Han, Duhyun ;
Lee, Jason K. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (06) :742-743
[15]   Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database [J].
Jensen, Elizabeth T. ;
Martin, Christopher F. ;
Kappelman, Michael D. ;
Dellon, Evan S. .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2016, 62 (01) :36-42
[16]   Elemental diet improves steroid-dependent eosinophilic gastroenteritis and reverses growth failure [J].
Justinich, C ;
Katz, A ;
Gurbindo, C ;
Lepage, G ;
Chad, Z ;
Bouthillier, L ;
Seidman, E .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1996, 23 (01) :81-85
[17]  
Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO
[18]  
2-1
[19]   Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases [J].
Kim, Erin M. ;
Randall, Cara ;
Betancourt, Renee ;
Keene, Staci ;
Lilly, Amy ;
Fowler, Mark ;
Dellon, Evan S. ;
Herfarth, Hans H. .
INFLAMMATORY BOWEL DISEASES, 2020, 26 (08) :1232-1238
[20]   Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis [J].
Kim, Hannah P. ;
Reed, Craig C. ;
Herfarth, Hans H. ;
Dellon, Evan S. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (12) :1992-1994